Carl Dieffenbach | Director, Division of AIDS

Carl Dieffenbach, Director, Division of AIDS, NIAID/NIH

Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related co-infections, and co-morbidities. With the ultimate goal of creating an “AIDS-free Generation,” the Division develops and supports the infrastructure and biomedical research needed to: 1) halt the spread of HIV through the development of an effective vaccine and biomedical prevention strategies that are safe and desirable; 2) develop novel approaches for the treatment and cure of HIV infection; 3) treat and/or prevent co-infections such as tuberculosis, and co-morbidities of greatest significance; and 4) foster partnerships with scientific and community stakeholders to develop and implement effective interventions. Dr. Dieffenbach received his bachelor’s degree in biochemistry from the University of Maryland in 1976 and his Ph.D. in biophysics from The Johns Hopkins University in 1984.


WVIC/WAC Day 1 - Nov 29 @ 08:30

Opening keynote presentation: Integrated Pandemic Preparedness

  • How vaccines, monoclonals, direct acting antiviral, agents targeting host factors have essential roles in mounting a broad, response to future pandemics
  • The need to develop and validate assays for detection of infection and measurement of immunity

WVIC/WAC Day 1 - Nov 29 @ 09:00

Panel: HIV – how can we end the epidemic?

  • How is new research bringing the goal of a cure within reach? 

  • HIV Vaccine, antibody, and antiviral landscape

  • Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccines 

    o How are we defining functional cure? 

    o Is the benchmark for a vaccine too high given the effectiveness of LAAV regimen?

  • To achieve success must reach all those disproportionately affected - How can PPP help to achieve this? 

WVIC/WAC Day 2 - Nov 30 @ 08:50

Chair’s opening remarks: The Antiviral Program for Pandemics (APP) and key support mechanisms available

WVIC/WAC Day 2 - Nov 30 @ 09:10

Panel: What is the future of COVID-19 therapeutics?

  • What are the key areas of focus for 2023 and onwards?
  • What novel therapies are being investigated?
  • Is there a particular part of the SARS-CoV-2 infection cycle being targeted?
  • Is there a silver bullet out there and what would it look like?
  • How to ensure therapeutic interventions are easily accessible?
  • How will the current and future COVID-19 therapeutics be used in the case of a new outbreak?
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall